eEF1A2 as a putative oncogene.
The first evidence for the role of the protein elongation factor eEF1A2 in tumorigenesis was reported by Anand and colleagues who demonstrated that eEF1A2 is overexpressed in about 30% of ovarian tumors and some established ovarian cancer cells. This abnormal expression correlates with a poor prognosis. Since this discovery, there have been several reports suggesting eEF1A2 as a diagnostic marker in various cancers. This review highlights the oncogenic potential of eEF1A2.
Lee
Mee-Hyun
MH
National Research Laboratory of Molecular Carcinogenesis and Chemoprevention, College of Pharmacy and Cancer Research Institute, Seoul National University, Seoul, Korea.
Surh
Young-Joon
YJ
D014408:Biomarkers, Tumor / Q000235:genetics; D001943:Breast Neoplasms / Q000235:genetics / Q000473:pathology*; D005260:Female; D005784:Gene Amplification; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D009857:Oncogenes / Q000235:genetics*; D010051:Ovarian Neoplasms / Q000235:genetics / Q000473:pathology*; D020648:Peptide Elongation Factor 1 / Q000235:genetics*; D011379:Prognosis
D014408:Biomarkers, Tumor; C503234:EEF1A2 protein, human; D020648:Peptide Elongation Factor 1